CD19 and precursor B-cell acute lymphoblastic leukemia: The approval of the anti-CD19 CAR T cell product tisagenlecleucel by FDA and European Medicinal Agency (EMA) for the treatment of relapsed pediatric B-ALL represents the start of a new era in acute leukemia therapy.